All the news Showing 10 of 81 articles from: TreatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 30 November 2017 Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in ... REP 2139 combination therapy leads to functional control of hepatitis B virus Liz Highleyman / 29 November 2017 A majority of people with chronic hepatitis B treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve 'functional control' of hepatitis B ... Besifovir and tenofovir exalidex look promising as new hepatitis B drug Liz Highleyman / 04 May 2017 Two investigational nucleotide analogue antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the International Liver Congress last week in Amsterdam. ... EASL releases updated hepatitis B guidelines at International Liver Congress Liz Highleyman / 26 April 2017 The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection – the first update since 2012 – during a ... Switching to TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 26 April 2017 People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at ... Statins reduce risk of decompensation for people with HCV- and HBV-related cirrhosis Michael Carter / 18 April 2017 Treatment with statins reduces the risk of decompensated liver disease for people with cirrhosis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), investigators from Taiwan report in the online edition ... Is better treatment reducing liver cancer among people with hepatitis B? Liz Highleyman / 23 February 2017 The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among people with chronic hepatitis B treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD ... Tenofovir alafenamide approved for hepatitis B in Europe Liz Highleyman / 16 January 2017 The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis B virus (HBV) infection, according ... GS-4774 therapeutic vaccine shows little efficacy in people with hepatitis B Liz Highleyman / 08 December 2016 An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well tolerated but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, ... Nucleic acid polymers reduce HBsAg levels and improve control of hepatitis B virus Liz Highleyman / 27 November 2016 The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small ... ← Prev1...23456...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive